期刊文献+

糖基化终产物对人肾小球系膜细胞半乳糖凝集素-3基因表达的影响

Effect of advanced glycation end products on the gene expression of galectin-3 in cultured human renal mesangial cells
下载PDF
导出
摘要 目的:研究糖基化终产物(AGEs)对人肾小球系膜细胞半乳糖凝集素-3(galectin-3)表达的影响。方法:将培养的人肾小球系膜细胞(HRMC)用不同浓度(50、100、200及400 mg.L-1)的AGEs干预24 h或同一浓度(200 mg.L-1)的AGEs干预0、24、48及72 h,以无血清培养基(DMEM)和相应浓度的牛血清白蛋白(BSA)为对照。用RT-PCR检测细胞中半乳糖凝集素-3的mRNA水平。结果:不同浓度AGEs组HRMC的半乳糖凝集素-3 mRNA水平与对照组相比均有显著差异(P<0.01),且随着AGEs浓度的增高,半乳糖凝集素-3 mRNA水平也逐渐增高(P<0.05);AGEs干预HRMC 24、48、72 h,半乳糖凝集素-3mRNA水平与对照组相比有显著差异(P<0.05),且随着干预时间的延长,半乳糖凝集素-3 mRNA水平也逐渐增高(P<0.01)。结论:AGEs以时间及剂量依赖的方式促进HRMC半乳糖凝集素-3 mRNA的表达。 Objective To study the effect of advanced glycation end products(AGEs) on the expression of galecfin- 3 in cultured human renal mesangial cells(HRMC). Methods The AGEs-BSA was prepared by incubating bovine serum albumin(BSA) with glucose. The cultured HRMC were intervened with the same concentration of BSA and AGEs- BSA(50,100,200,400 mg · L^-1 ) for 24 h or 200 mg · L^-1 AGEs-BSA for 0,24,48 or 72 h respectively. The mRNA expression of galectin-3 in HRMC were analyzed by RT-PCR. Results Compared with that in cells incubated with DMEM and BSA,the level of galectin-3 mRNA in cells incubated with 50,100 or 200,400 mg · L^-1 AGEs-BSA respectively for 24 h ( P 〈 0.01 ) or with 200 mg· L ^-1 AGEs- BSA for 0,24,48 or 72 h respectively ( P 〈 0.05 ) increased significantly. Moreover, with the increased concentration of AGEs- BSA ( P 〈 0.05 ) or the expanded incubating time ( P 〈 0.01 ), the level of galectin-3 mRNA increased. Conclusion The AGEs- BSA can stimulate the expression of galectin- 3 in cultured HRMC in a concentration- and time-dependent manner.
出处 《东南大学学报(医学版)》 CAS 2006年第3期174-177,共4页 Journal of Southeast University(Medical Science Edition)
基金 江苏省教育厅高校自然科学研究项目(02KJA320001) 教育部科学技术研究重点项目(204051)
关键词 糖基化终产物 人肾小球系膜细胞 糖尿病肾病 半乳糖凝集素-3 基因表达 advanced glycation end products human renal mesangial cells diabetic nephropathy galectin-3 gene expression
  • 相关文献

参考文献11

  • 1FRIEDMAN E A.Renal syndromes in diabetes[J].Endocinol Metab Clin North Am,1996,25:293-324.
  • 2SINGH R,BARDEN A,MORI T,et al.Advanced glycation end products:a review[J].Diabetologia,2001,44:129-146.
  • 3VLASSARA H,LI Y M,IMANI Y,et al.Identification of galectin-3 as a high-affinity binding protein for advanced glycosylation end products (AGE):a new member of the AGE-receptor complex[J].Mol Med,1995,1:634-646.
  • 4李世云,孙子林,刘乃丰,李丽,刘必成.AGEs-BSA对人肾系膜细胞分泌RANTES的影响初探[J].东南大学学报(医学版),2003,22(6):363-365. 被引量:8
  • 5SEKI N,HASHIMOTO N,SANO H,et al.Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells[J].Metab,2003,52:1558-1563.
  • 6ZHU W,SANO H,NAGAI R,et al.The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins[J].Biochem Biophys Res Commun,2001,280:1183-1188.
  • 7KIKUCHI Y,KOBAYASHI S,HEMMI N,et al.Galectin-3-positive cell infiltration in human diabetic nephropathy[J].Nephrol Dial Transpl,2004,19:602-607.
  • 8CANDIDO R,FORBES J M,THOMAS M C,et al.A breaker of AGEs attenuates diabetes-induced myocardial structural changes[J].Circ Res,2003,92:785-792.
  • 9PUGLIESE G,PRICCI F,LETO L,et al.The diabetic milieu modulates the AGE-receptor complex in the mesangium by inducing or up-regulating galectin-3 expression[J].Diabetes,2000,49:1249-1257.
  • 10PUGLIESE G,PRICCI F,IACOBINI C,et al.Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knock-out mice[J].FASEB J,2001,15:2471-2479.

二级参考文献24

  • 1WANG S N, laPAGE J, HIRSCHBERG R. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy[J]. Kidney Int, 2000, 57: 1002-1014.
  • 2SINGH R, BARDEN A, MORI T, et al. Advanced glycation end products: a review[J]. Diabetologia, 2001,44 : 129-146.
  • 3ROVIN B H, SCHREINER G F. Cell-mediated immunity in glomerular disease[J]. Annu Rev Med, 1991,42.25-33.
  • 4YOUNG B A, JOHNSON R J, ALPERS C E, et al. Cellular events in the evolution of experimental diabetic nephropathy[J]. Kidney Int, 1995,47:935-944.
  • 5BACON K B, PREMACK B A, GARDNER P, et al. Activation of dual T cell signaling pathways by the chemokine RANTES[ J ]. Science, 1995,269 : 1727-1730.
  • 6KUNA P,REDDIGARI S R,SCHALL T J ,et al. RANTES,a monocyte and T lymphocyte chemoatactic cytokine releases histarnine from human basophils[ J ]. J Immunol, 1992,149 : 636-642.
  • 7SCHALL T J, BACON K, TOY K J, et al. Selective attraction of monocyte and T lymphocytes of memory phenotype by cytokine RANTES[ J ]. Nature, 1990,347 : 669-671.
  • 8NATORI Y, SEKIGUCHI M, NATORI Y. Expression of mRNA of C-C chernokines in experimental crescentic glomerulonephritis[ J ]. J Am Soc Nephrol, 1995,6: 845.
  • 9Stern DM, Yan SD, Yan SF, et al. Receptor for advanced glycation endproducts(RAGE) and the complications of diabetes. Ageing Res Rev,2002,1:1-15.
  • 10Ohgami N, Nagai R, Ikemoto M, et al. CD36, serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complications, 2002,16: 56-59.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部